Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Argus Health
UBS
Farmers Insurance
Moodys
Deloitte
Boehringer Ingelheim
Merck
Chinese Patent Office

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FAMCICLOVIR

« Back to Dashboard

Clinical Trials for Famciclovir

Trial ID Title Status Sponsor Phase Summary
NCT00098046 Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Completed Novartis Phase 3 Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is not a standard of care in immunocompetent children, but is recommended whenever a risk of complication exists. This study will evaluate the safety and blood levels of a new formulation of famciclovir in children 1-12 years of age.
NCT00098059 Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection Completed Novartis Pharmaceuticals Phase 3 This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics (PK) and safety. In Part B, patients will receive multiple doses of famciclovir alone or with concomitant oral anti-herpes therapy to assess safety and tolerability. Part B will start only after PK data from Part A had been analyzed.
NCT00129818 A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Completed Novartis Phase 4 The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity.
NCT00171990 Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes Completed Novartis Phase 3 This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Famciclovir

Condition Name

Condition Name for Famciclovir
Intervention Trials
Genital Herpes 4
Herpes Zoster 2
Herpes Simplex 2
Herpes Nos 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Famciclovir
Intervention Trials
Herpes Genitalis 6
Herpes Labialis 3
Herpes Simplex 2
Herpes Zoster 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Famciclovir

Trials by Country

Trials by Country for Famciclovir
Location Trials
United States 78
Canada 7
Brazil 5
Panama 3
Australia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Famciclovir
Location Trials
Texas 6
Missouri 5
Ohio 4
North Carolina 4
Alabama 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Famciclovir

Clinical Trial Phase

Clinical Trial Phase for Famciclovir
Clinical Trial Phase Trials
Phase 4 4
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Famciclovir
Clinical Trial Phase Trials
Completed 16
Active, not recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Famciclovir

Sponsor Name

Sponsor Name for Famciclovir
Sponsor Trials
Novartis 7
Novartis Pharmaceuticals 3
EMS 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Famciclovir
Sponsor Trials
Industry 20
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Express Scripts
Baxter
Argus Health
Queensland Health
Federal Trade Commission
Moodys
Merck
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.